Abiomed Announces Preliminary Fourth Quarter Revenue of $43.7 Million, Driven by Record Number of Patients Supported

Abiomed Announces Preliminary Fourth Quarter Revenue of $43.7 Million, Driven
by Record Number of Patients Supported

Full Fiscal Year 2013 Revenue Exceeds Annual Revenue Guidance

DANVERS, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc.
(Nasdaq:ABMD), a leading provider of breakthrough heart support technologies,
today reported preliminary fourth quarter fiscal 2013 revenue of $43.7
million, up 17% compared to revenue of $37.3 million in the same period of
fiscal 2012, and up 14% compared to revenue of $38.3 million in third quarter
fiscal 2013. Abiomed also reported preliminary full fiscal year 2013 revenue
of $158.1 million, up 25% compared to $126.4 million for fiscal year 2012.

Preliminary fiscal fourth quarter worldwide Impella revenue totaled $39.3
million, up 22% compared to revenue of $32.3 million during the same period of
the prior year. For the full fiscal year 2013, preliminary worldwide Impella
revenue totaled $140.3 million, up 31% compared to $106.9 million for fiscal
year 2012.

Preliminary fiscal fourth quarter U.S. Impella revenue grew 22% to $36.5
million from $29.9 million in the prior year.During the quarter, an
additional 30 hospitals purchased Impella 2.5 bringing the total to 748 U.S.
Impella customer sites and an additional 55 hospitals purchased Impella CP,
bringing the total Impella CP sites to 101.For the full fiscal year 2013,
preliminary U.S. Impella revenue totaled $131.3 million, up 32% compared to
fiscal year 2012.

"With an outstanding performance in the fourth quarter, we were able to exceed
our annual revenue guidance for the third straight year.This reflects the
strength of physician demand for Impella and the commitment of our field team
to patients," said Michael R. Minogue, Chairman, President and Chief Executive
Officer, Abiomed.

The Company will host a conference call to discuss the fourth quarter fiscal
year 2013 results on Thursday, May 2, 2013, at 8:00 a.m. ET with Michael R.
Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen,
Vice President and Chief Financial Officer; and Susan V. Lisa, Senior Director
of Investor Relations and Corporate Development.

To listen to the call live, please tune into the webcast via
http://investor.abiomed.com or dial (877) 638-9567; the international number
is (253) 237-1032. A replay of this conference call will be available
beginning at 11 a.m. ET May 2, 2013 through 11:59 p.m. ET on May 10, 2013. The
replay phone number is (855) 859-2056; the international number is (404)
537-3406. The replay access code is 36674557.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of
medical devices that provide circulatory support.Our products are designed to
enable the heart to rest by improving blood flow and/or performing the pumping
of the heart. For additional information please visit: www.abiomed.com

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements
regarding development of Abiomed's existing and new products, the Company's
progress toward commercial growth, and future opportunities and expected
regulatory approvals. The Company's actual results may differ materially from
those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and
related regulatory approvals, including the potential for future losses,
complex manufacturing, high quality requirements, dependence on limited
sources of supply, competition, technological change, government regulation,
litigation matters, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the Company's filings
with the Securities and Exchange Commission, including the most recently filed
Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are
cautioned not to place undue reliance on any forward-looking statements, which
speak only as of the date of this release. The Company undertakes no
obligation to publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or circumstances
that occur after the date of this release or to reflect the occurrence of
unanticipated events.

CONTACT: Susie Lisa, CFA
         Senior Director, Investor Relations and Corporate Development
         978-646-1590
         slisa@abiomed.com
        
         Aimee Genzler
         Corporate Communications Manager
         978-646-1553
         agenzler@abiomed.com

Abiomed Logo